Literature DB >> 15154827

A problem-oriented approach to safety issues in drug development and beyond.

Joanna F Haas1.   

Abstract

Human safety issues arise throughout the life cycle of pharmaceutical products and relevant information comes from a multitude of sources. Assessment and management of risks to humans requires a problem-based analysis to bring together relevant information regardless of source. The Safety Evaluation Plan (SEP) is a tool to support problem-oriented safety analysis. Safety issues are specified and the evaluation and management of each problem is based on a status summary that integrates the most current information from all relevant sources. The status summary is updated regularly during the course of clinical development to reflect the results of new studies and new clinical trials. In the postmarketing period, relevant postmarketing data is incorporated. Recent regulatory initiatives emphasise early identification of product safety risks so that appropriate risk-management measures can be instituted at the time of approval. A problem-oriented approach supports growing regulatory expectations regarding risk assessment and risk management. The problem-oriented approach facilitates early identification of safety issues and an evidence-based approach to their evaluation. Proactive management of safety problems leads to prompt assessment of risks and timely and appropriate steps aimed at risk reduction. The SEP provides a single global assessment for each safety issue. Regulatory submissions for pharmaceutical and biological products are organised by type of information. International Conference of Harmonisation documents covering clinical safety issues structure and analyse information separately by type, for example, adverse events, serious adverse events, laboratory data, vital signs, etc. A problem-oriented analysis would need to find a place in the regulatory process. A problem-oriented approach to safety cuts across typical structures in the pharmaceutical industry where different groups handle preclinical, clinical and postmarketing safety information. The SEP can improve communication within the company and externally. Nonetheless, supporting structures need to be adapted to support such an interdisciplinary process. Overall, the problem-oriented approach, supported by a SEP, contributes to realistic expectations and sustained credibility when dealing with safety issues.

Entities:  

Mesh:

Year:  2004        PMID: 15154827     DOI: 10.2165/00002018-200427080-00007

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  7 in total

Review 1.  Drug-induced prolongation of the QT interval.

Authors:  Dan M Roden
Journal:  N Engl J Med       Date:  2004-03-04       Impact factor: 91.245

Review 2.  Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiency.

Authors:  Matthew P McCormack; Terence H Rabbitts
Journal:  N Engl J Med       Date:  2004-02-26       Impact factor: 91.245

3.  Medical records that guide and teach.

Authors:  L L Weed
Journal:  N Engl J Med       Date:  1968-03-21       Impact factor: 91.245

4.  Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.

Authors:  F E Silverstein; G Faich; J L Goldstein; L S Simon; T Pincus; A Whelton; R Makuch; G Eisen; N M Agrawal; W F Stenson; A M Burr; W W Zhao; J D Kent; J B Lefkowith; K M Verburg; G S Geis
Journal:  JAMA       Date:  2000-09-13       Impact factor: 56.272

Review 5.  Assessment of risks associated with cardiovascular gene therapy in human subjects.

Authors:  J M Isner; P R Vale; J F Symes; D W Losordo
Journal:  Circ Res       Date:  2001-08-31       Impact factor: 17.367

6.  A randomized open-label study of the impact of quetiapine versus risperidone on sexual functioning.

Authors:  Rikus Knegtering; Stynke Castelein; Han Bous; Just Van Der Linde; Richard Bruggeman; Herman Kluiter; Robert J van den Bosch
Journal:  J Clin Psychopharmacol       Date:  2004-02       Impact factor: 3.153

Review 7.  Controversy surrounding the safety of cerivastatin.

Authors:  Michael H Davidson
Journal:  Expert Opin Drug Saf       Date:  2002-09       Impact factor: 4.250

  7 in total
  1 in total

Review 1.  Pharmacovigilance during the pre-approval phases: an evolving pharmaceutical industry model in response to ICH E2E, CIOMS VI, FDA and EMEA/CHMP risk-management guidelines.

Authors:  Craig G Hartford; Kasia S Petchel; Hani Mickail; Susana Perez-Gutthann; Mary McHale; John M Grana; Paula Marquez
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.